Open AccessThis article is
- freely available
Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway
Division of Rheumatic Diseases, Departments of Medicine & Anatomy, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106, USA
Received: 26 March 2010; in revised form: 20 April 2010 / Accepted: 11 May 2010 / Published: 12 May 2010
Abstract: A skewed ratio of pro-inflammatory to anti-inflammatory cytokines, elevated growth factor synthesis and T- and B-lymphocyte activation are 3 hallmarks of rheumatoid arthritis (RA) pathology. Interleukin-6 (IL-6), IL-7, IL-17, IL-12/IL-23 and growth factors, granulocyte macrophage-colony stimulating factor, IL-3, and erythropoietin activate the Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) pathway. Evidence showed that STAT protein phosphorylation (p-STAT) by activated JAKs is permissive for p-STAT to act as transcription factors by binding to STAT-responsive gene promoter sequences. This event is critical for perpetuating RA, in part, by up-regulating pro-inflammatory cytokine gene transcription. Activation of JAK/STAT by cytokines and growth factors can induce ‘cross-talk’ with other signaling pathways by which Stress-Activated Protein/Mitogen-Activated Protein Kinase (SAP/MAPK) and Phosphatidylinositide-3-Kinase (PI3K)-mediated signaling are also activated. JAK-specific small molecule inhibitors (SMIs) were developed to test whether JAK/STAT pathway blockade would regulate autoimmune-mediated inflammation. JAK-specific SMI blockade inhibited p-STAT induced by pro-inflammatory cytokines in vitro. Systemically administered JAK-specific SMI blockade also ameliorated biomarkers of inflammation in well-validated arthritis animal models. A few JAK-specific SMIs have made their way into RA clinical trials. In fact, the JAK3-specific SMI, CP-690,500 is the first JAK/STAT SMI to be assessed for clinical efficacy in a Phase III RA trial.
Keywords: arthritis; autoimmune; Janus kinase; signal transducers and activators of transcription; small molecule inhibitor
Citations to this Article
Cite This Article
MDPI and ACS Style
Malemud, C.J. Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway. Pharmaceuticals 2010, 3, 1446-1455.
Malemud CJ. Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway. Pharmaceuticals. 2010; 3(5):1446-1455.
Malemud, Charles J. 2010. "Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway." Pharmaceuticals 3, no. 5: 1446-1455.